The North America Autoimmune Disease Diagnostics Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.68 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).
Moreover, increasing developments by major market players in the country are also expected to boost market growth. For instance, in April 2022, Quanterix received a breakthrough device designation by United States FDA for the ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS)-expected to boost the market growth in the country. For instance, according to data updated by the National Institute of Environmental Health Sciences in May 2022, autoimmune diseases are estimated to affect more than 24 million people in the United States. Also, an additional 8 million people are said to have autoantibodies, blood molecules that indicate a person's chance of developing autoimmune disease. Thus, the rising prevalence of autoimmune disorders will boost segment growth.
Furthermore, according to the data published by the International Diabetes Federation in 2022, it was estimated that 32.2 million people were living with diabetes in the United States in 2021, and it is expected to reach 34.8 million by 2030. The same source also stated that around 1.5 million were living with type 1 diabetes in the United States in 2022. Thus, the high prevalence of diabetes in the country is expected to boost segment growth.
Moreover, increasing developments by major market players in the country are also expected to boost market growth. For instance, in April 2022, Quanterix received a breakthrough device designation by United States FDA for the ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS). Hence, the factors above, such as the rising prevalence of autoimmune disorders and the increasing research and development on autoimmune diseases, are expected to boost segment growth.
The North America Autoimmune Disease Diagnostics Market is fragmented in nature. The market comprises several major market players who are focusing on R&D activities and significant growth strategies. Recently, a few diagnostic companies entered into strategic partnerships with hospitals. This trend is expected to continue over the next few years, to meet the high volume of patient needs across different regions. Some of the key players in the North American autoimmune disease diagnostics market are Abbott Laboratories, Biomérieux, Bio-rad Laboratories, Euroimmun AG, and Trinity Biotech, among others.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook